DiaMedica Therapeutics

Yahoo Finance • 11 days ago

After-Hours Earnings Report for March 30, 2026 : PRGS, PHR, DMAC, AIRJ, SPCE, HQI, SGMO, RNXT, INLX, FTHM

The following companies are expected to report earnings after hours on 03/30/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Progress Software Corporation (PRGS)is reporting for the quarter ending Febru... Full story

Yahoo Finance • last month

Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsight

DelveInsight Business Research LLP The growth of the acute ischemic stroke market is expected to be driven primarily by increased awareness of symptoms, advances in acute stroke care, and a robust pipeline of potential candidates such as... Full story

Yahoo Finance • 4 months ago

Huge Insider Buying in MGM and Salesforce

JasonDoiy / Getty Images As the year begins to wind down, investors are looking to position themselves for 2026. In recent days, insiders, including beneficial owners, at Crescent Biopharma Inc. (NASDAQ: CBIO), MGM Resorts International (... Full story

Yahoo Finance • 4 months ago

After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance

(RTTNews) - Biotechnology stocks saw notable movement in after-hours trading on Monday, with several companies posting strong gains. Below is a structured look at the key movers and the developments driving their performance. Exicure, Inc... Full story

Yahoo Finance • 5 months ago

Microsoft initiated, Home Depot downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Baird upgraded Circle Internet(CRCL) t... Full story

Yahoo Finance • 8 months ago

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Reports Q2 2025 Earnings: Narrower Loss and Promising Clinical Updates Drive Stock Surge

DiaMedica Therapeutics Inc. (NASDAQ:DMAC [https://www.chartmill.com/stock/quote/DMAC]) reported its second-quarter 2025 financial results, posting a net loss of $7.7 million, or $0.18 per share, compared to a net loss of $5.1 million, or $... Full story

Yahoo Finance • 8 months ago

DiaMedica therapeutics (DMAC): Trill AB buys $5.4m in shares

Trill AB, a ten percent owner of DiaMedica Therapeutics Inc (NASDAQ:DMAC), reported purchasing 1,542,857 common shares of the company on July 23, 2025. The shares were bought at a price of $3.5, totaling approximately $5,399,999. The stock... Full story

Yahoo Finance • 8 months ago

DiaMedica therapeutics (DMAC) shareholder TomEnterprise Private AB buys $10M in stock

A 10% owner, TomEnterprise Private AB, associated with Thomas Von Koch, reported purchasing 2,857,142 shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) common stock on July 23, 2025. The shares were bought at a price of $3.5, with the to... Full story

Yahoo Finance • 9 months ago

DiaMedica Therapeutics raises $30 million in private placement

* DiaMedica Therapeutics (NASDAQ:DMAC [https://seekingalpha.com/symbol/DMAC]) announced on Monday definitive agreements for a $30.1 million private placement of common shares led by current investors. * Pursuant to the terms of the sec... Full story

Yahoo Finance • 9 months ago

DiaMedica secures $30.1 million in private placement for clinical trials

MINNEAPOLIS - DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a biopharmaceutical company with a strong financial health score of 2.31 according to InvestingPro, announced Monday it has secured $30.1 million in a private placement of common sha... Full story

Yahoo Finance • 9 months ago

DiaMedica shares drop 35% following InvestingPro's overvalued warning

In December 2024, InvestingPro’s Fair Value model identified (NASDAQ:DMAC) as significantly overvalued at $6.41, demonstrating the power of data-driven investment analysis. Seven months later, the stock trades at $4.18, validating the mode... Full story

Yahoo Finance • 9 months ago

DiaMedica stock price target raised to $12 from $10 at H.C. Wainwright

Investing.com - H.C. Wainwright raised its price target on DiaMedica Therapeutics Inc. (NASDAQ:DMAC) to $12.00 from $10.00 on Friday, while maintaining a Buy rating on the stock. Currently trading at $3.93, the clinical-stage biotech compa... Full story

Yahoo Finance • 9 months ago

DiaMedica gains on positive mid-stage trial data for lead drug in preeclampsia

[Pre-eclampsia, a multi-system disorder during pregnancy including high blood pressure and proteinuria.] Md Saiful Islam Khan/iStock via Getty Images * DiaMedica Therapeutics (NASDAQ:DMAC [https://seekingalpha.com/symbol/DMAC]) traded h... Full story

Yahoo Finance • 9 months ago

DiaMedica reports positive interim results for preeclampsia treatment

MINNEAPOLIS - DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company with a market capitalization of $171 million, announced positive interim results from its Phase 2 study of DM199 for the treatment of preec... Full story

Yahoo Finance • 10 months ago

DiaMedica Therapeutics to be included in the Russell 2000 and 3000 indexes

* DiaMedica Therapeutics (NASDAQ:DMAC [https://seekingalpha.com/symbol/DMAC]) announced [https://seekingalpha.com/pr/20145627-diamedica-therapeutics-announces-inclusion-in-the-russell-2000-and-russell-3000-indexes] on Tuesday its upcomin... Full story

Yahoo Finance • 10 months ago

DiaMedica Therapeutics Announces Inclusion in the Russell 2000 ® and Russell 3000 ® Indexes

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition a... Full story

Yahoo Finance • 2 years ago

Billionaire Lee Cooperman’s 10 Stock Picks with Huge Upside Potential

In this article, we discuss billionaire Lee Cooperman's 10 stock picks with huge upside potential. To skip the details of Mr. Cooperman’s life and investment strategy, go directly to Billionaire Lee Cooperman's 5 Stock Picks with Huge Upsi... Full story

Yahoo Finance • 3 years ago

Q1 2023 DiaMedica Therapeutics Inc Earnings Call

Participants Dietrich John Pauls; President, CEO & Director; DiaMedica Therapeutics Inc. Scott B. Kellen; CFO & Company Secretary; DiaMedica Therapeutics Inc. Alexander David Nowak; Senior Research Analyst; Craig-Hallum Capital Group LL... Full story